CD8A and leukemia: Notably, the RHAMM-derived peptide R3 has been shown to induce specific CD8+ T cell responses in both healthy donors and CML patients following allogeneic stem cell transplantation, hinting at the peptide’s capability to enhance graft-versus-leukemia effects [108].